FDA approval for Ryoncil boosts Mesoblast shares by 46pc

A breakthrough approval by the US Food and Drug Administration for Mesoblast’s (ASX: MSB) treatment for a common stem cell transplant complication has driven a 40 per cent surge in shares of the Melbourne-based biotech.

Mesoblast shares shot to a peak of $2.90 this afternoon, their highest…